Cargando…
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927319/ https://www.ncbi.nlm.nih.gov/pubmed/31406976 http://dx.doi.org/10.1093/annonc/mdz221 |
| _version_ | 1783482284524961792 |
|---|---|
| author | Long, G V Flaherty, K T Stroyakovskiy, D Gogas, H Levchenko, E de Braud, F Larkin, J Garbe, C Jouary, T Hauschild, A Chiarion-Sileni, V Lebbe, C Mandalá, M Millward, M Arance, A Bondarenko, I Haanen, J B A G Hansson, J Utikal, J Ferraresi, V Mohr, P Probachai, V Schadendorf, D Nathan, P Robert, C Ribas, A Davies, M A Lane, S R Legos, J J Mookerjee, B Grob, J -J |
| author_facet | Long, G V Flaherty, K T Stroyakovskiy, D Gogas, H Levchenko, E de Braud, F Larkin, J Garbe, C Jouary, T Hauschild, A Chiarion-Sileni, V Lebbe, C Mandalá, M Millward, M Arance, A Bondarenko, I Haanen, J B A G Hansson, J Utikal, J Ferraresi, V Mohr, P Probachai, V Schadendorf, D Nathan, P Robert, C Ribas, A Davies, M A Lane, S R Legos, J J Mookerjee, B Grob, J -J |
| author_sort | Long, G V |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6927319 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69273192019-12-27 Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Long, G V Flaherty, K T Stroyakovskiy, D Gogas, H Levchenko, E de Braud, F Larkin, J Garbe, C Jouary, T Hauschild, A Chiarion-Sileni, V Lebbe, C Mandalá, M Millward, M Arance, A Bondarenko, I Haanen, J B A G Hansson, J Utikal, J Ferraresi, V Mohr, P Probachai, V Schadendorf, D Nathan, P Robert, C Ribas, A Davies, M A Lane, S R Legos, J J Mookerjee, B Grob, J -J Ann Oncol Corrigenda Oxford University Press 2019-11 2019-08-13 /pmc/articles/PMC6927319/ /pubmed/31406976 http://dx.doi.org/10.1093/annonc/mdz221 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Corrigenda Long, G V Flaherty, K T Stroyakovskiy, D Gogas, H Levchenko, E de Braud, F Larkin, J Garbe, C Jouary, T Hauschild, A Chiarion-Sileni, V Lebbe, C Mandalá, M Millward, M Arance, A Bondarenko, I Haanen, J B A G Hansson, J Utikal, J Ferraresi, V Mohr, P Probachai, V Schadendorf, D Nathan, P Robert, C Ribas, A Davies, M A Lane, S R Legos, J J Mookerjee, B Grob, J -J Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| title | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| title_full | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| title_fullStr | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| title_full_unstemmed | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| title_short | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| title_sort | dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic braf v600e/k-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
| topic | Corrigenda |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927319/ https://www.ncbi.nlm.nih.gov/pubmed/31406976 http://dx.doi.org/10.1093/annonc/mdz221 |
| work_keys_str_mv | AT longgv dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT flahertykt dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT stroyakovskiyd dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT gogash dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT levchenkoe dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT debraudf dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT larkinj dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT garbec dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT jouaryt dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT hauschilda dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT chiarionsileniv dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT lebbec dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT mandalam dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT millwardm dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT arancea dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT bondarenkoi dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT haanenjbag dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT hanssonj dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT utikalj dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT ferraresiv dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT mohrp dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT probachaiv dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT schadendorfd dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT nathanp dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT robertc dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT ribasa dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT daviesma dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT lanesr dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT legosjj dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT mookerjeeb dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study AT grobjj dabrafenibplustrametinibversusdabrafenibmonotherapyinpatientswithmetastaticbrafv600ekmutantmelanomalongtermsurvivalandsafetyanalysisofaphase3study |